ArticleClinical and translational radiation oncology2025
Microscopic intramural spread in patients with rectal cancer after neoadjuvant chemoradiation.
Article in Clinical and translational radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigates microscopic intramural spread (MIS) after neoadjuvant (chemo)radiotherapy on Total Mesorectal Excision (TME) specimens of rectal cancer patients and explores the necessity of an additional treatment margin for endorectal radiation boosts (for example through contact brachytherapy (CXB)) or local excisions. Methods: A cohort of patients from Maastricht University Medical Center (MUMC + ) treated between 2016 and 2022 was analyzed. Patients underwent MRI, CT scans, and sigmoidoscopy six weeks after radiotherapy, followed by surgery. Pathological analysis of TME specimens, including whole mount macro-cassettes, was performed to measure residual macroscopic tumor and MIS. Fragmented and continuous MIS were recorded parallel and perpendicular to the bowel wall. Results: Out of 54 patients, 37 (69%) exhibited no MIS. MIS was observed in 4/18 (22%) of patients with ycT1-2 tumors and 13/36 (36%) of patients with ycT3-4 tumors. 4 patients (7%) showed continuous MIS and 15 (28%) showed fragmented MIS. No patients with ypT1-2 had MIS. Conclusions: 69% of patients do not retain MIS post-neoadjuvant therapy. Knowledge of tumor thickness seems crucial for patient selection for CXB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.